268 related articles for article (PubMed ID: 15457477)
1. Results of anakinra treatment in rheumatoid arthritis patients previously treated with tumor necrosis factor alpha blockade: comment on the article by Buch et al.
Saxne T; Larsson L; Geborek P
Arthritis Rheum; 2004 Sep; 50(9):3049-50; author reply 3050-1. PubMed ID: 15457477
[No Abstract] [Full Text] [Related]
2. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade: comment on the article by Buch et al.
Schiff MH
Arthritis Rheum; 2005 Jan; 52(1):364-5; author reply 365. PubMed ID: 15641081
[No Abstract] [Full Text] [Related]
3. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.
Cohen SB
Rheum Dis Clin North Am; 2004 May; 30(2):365-80, vii. PubMed ID: 15172046
[TBL] [Abstract][Full Text] [Related]
4. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade.
Buch MH; Bingham SJ; Seto Y; McGonagle D; Bejarano V; White J; Emery P
Arthritis Rheum; 2004 Mar; 50(3):725-8. PubMed ID: 15022311
[TBL] [Abstract][Full Text] [Related]
5. [New treatments for rheumatoid arthritis].
Girault V; Flipo RM
Soins; 2004 Sep; (688):37-8. PubMed ID: 15515847
[No Abstract] [Full Text] [Related]
6. Anakinra: the first interleukin-1 inhibitor in the treatment of rheumatoid arthritis.
Kary S; Burmester GR
Int J Clin Pract; 2003 Apr; 57(3):231-4. PubMed ID: 12723729
[TBL] [Abstract][Full Text] [Related]
7. Safety of extended treatment with anakinra in patients with rheumatoid arthritis.
Fleischmann RM; Tesser J; Schiff MH; Schechtman J; Burmester GR; Bennett R; Modafferi D; Zhou L; Bell D; Appleton B
Ann Rheum Dis; 2006 Aug; 65(8):1006-12. PubMed ID: 16396977
[TBL] [Abstract][Full Text] [Related]
8. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv2-14. PubMed ID: 16239380
[No Abstract] [Full Text] [Related]
9. [Anakinra in the treatment of rheumatoid arthritis].
Loft AG; Tarp U; Thomsen BS
Ugeskr Laeger; 2003 Sep; 165(39):3720-4. PubMed ID: 14558384
[No Abstract] [Full Text] [Related]
10. Moraxella catarrhalis-induced septic arthritis of a prosthetic knee joint in a patient with rheumatoid arthritis treated with anakinra: comment on the article by Schiff et al.
Leonardou A; Giali S; Daoussis D; Siambi V; Gogos H; Liossis SN
Arthritis Rheum; 2005 Apr; 52(4):1337; author reply 1338. PubMed ID: 15818660
[No Abstract] [Full Text] [Related]
11. Kineret: efficacy and safety in daily clinical practice: an interim analysis of the Kineret response assessment initiative (kreative) protocol.
Langer HE; Missler-Karger B
Int J Clin Pharmacol Res; 2003; 23(4):119-28. PubMed ID: 15224501
[TBL] [Abstract][Full Text] [Related]
12. Anakinra (Kineret) for rheumatoid arthritis.
Med Lett Drugs Ther; 2002 Feb; 44(1124):18-9. PubMed ID: 11856953
[No Abstract] [Full Text] [Related]
13. The 'alphabet' of rheumatoid arthritis treatment.
Capriotti T
Medsurg Nurs; 2004 Dec; 13(6):420-8. PubMed ID: 15714747
[No Abstract] [Full Text] [Related]
14. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis.
Furst DE
Clin Ther; 2004 Dec; 26(12):1960-75. PubMed ID: 15823761
[TBL] [Abstract][Full Text] [Related]
15. Emerging biologic drugs for the treatment of rheumatoid arthritis.
Puppo F; Murdaca G; Ghio M; Indiveri F
Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
[TBL] [Abstract][Full Text] [Related]
16. Biologics in rheumatoid arthritis.
Sharma PK; Hota D; Pandhi P
J Assoc Physicians India; 2004 Mar; 52():231-6. PubMed ID: 15636315
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of refractory Schnitzler syndrome with anakinra: comment on the article by Hawkins et al.
Martinez-Taboada VM; Fontalba A; Blanco R; Fernández-Luna JL
Arthritis Rheum; 2005 Jul; 52(7):2226-7. PubMed ID: 15986356
[No Abstract] [Full Text] [Related]
18. Rheumatoid arthritis: guidelines for emerging therapies.
Blumberg SN; Fox DA
Am J Manag Care; 2001 Jun; 7(6):617-26. PubMed ID: 11439735
[TBL] [Abstract][Full Text] [Related]
19. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii2-ii12. PubMed ID: 15479866
[No Abstract] [Full Text] [Related]
20. [Interleukin-1 receptor antagonists in the treatment rheumatoid arthritis].
Zoń-Giebel A; Kotulska A; Giebel S; Cader SA; Kucharz EJ
Przegl Lek; 2002; 59(11):916-8. PubMed ID: 12715722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
